Pharmacological Modulation of Cognitive Control
Corresponding Organization :
Other organizations : Stanford Medicine, Boehringer Ingelheim (Germany)
Variable analysis
- Atomoxetine hydrochloride dose (5 mg/kg or 10 mg/kg)
- D-amphetamine hemisulfate dose (1 mg/kg or 2.5 mg/kg)
- HcrtR1 antagonist dose (2.5 mg/kg, 7.5 mg/kg, or 12.5 mg/kg)
- Performance on the Go/NoGo test
- Order of drug/dose administration (randomized)
- Washout period between treatments (at least 3 days)
- Route of administration (intraperitoneal injection for atomoxetine and D-amphetamine, oral gavage for HcrtR1 antagonist)
- Solvent used for drug preparation (0.9% saline for atomoxetine and D-amphetamine, 0.5% hydroxyethylcellulose and 0.015% Tween 80 in water for HcrtR1 antagonist)
- Saline injection 10 min prior to Go/NoGo test
- Vehicle solution for HcrtR1 antagonist via oral gavage 60 min prior to Go/NoGo test
- No treatment (not explicitly mentioned)
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!